Noopept

Overview

Noopept (GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic dipeptide developed in 1996 by Professor Tatiana Gudasheva at the Zakusov Institute of Pharmacology of the Russian Academy of Medical Sciences. Though often categorized with the racetam family due to its origin as a prodrug designed to mimic the pharmacological profile of piracetam, Noopept is structurally a dipeptide analog of the endogenous neuropeptide cycloprolylglycine (cPG) and does not contain the 2-pyrrolidone nucleus that defines true racetams. Noopept is approximately 1,000 times more potent than piracetam by weight, with effective oral doses in the 10–30 mg range compared to piracetam's 1,200–4,800 mg. This potency difference reflects both superior blood-brain barrier penetration (due to its dipeptide structure exploiting peptide transport systems) and distinct receptor-level mechanisms. Noopept is registered in Russia as a nootropic pharmaceutical under the trade name Noopept.

The cognitive-enhancing and neuroprotective effects of Noopept are mediated through several well-characterized mechanisms. After crossing the blood-brain barrier, Noopept is rapidly metabolized to cycloprolylglycine, which modulates both AMPA and NMDA glutamate receptors — enhancing excitatory neurotransmission and facilitating long-term potentiation (LTP) without the excitotoxicity risk of direct glutamate agonists. Critically, Noopept robustly upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex, driving neuroplasticity, synaptogenesis, and neuronal survival. Additional mechanisms include antioxidant activity (scavenging of reactive oxygen species and inhibition of calcium-mediated mitochondrial apoptosis), anti-inflammatory effects (suppression of neuroinflammatory cascades), and enhancement of alpha-wave cortical activity associated with relaxed alertness. Clinical studies in patients with mild cognitive impairment of vascular and traumatic origin demonstrated significant improvements in memory, attention, and overall cognitive function.

Noopept is typically administered at 10–30 mg daily, either orally or sublingually for faster absorption. The compound has a relatively short half-life (~60 minutes), though its neurotrophic effects (BDNF/NGF upregulation) persist beyond the acute pharmacokinetic window. Users commonly report improved memory consolidation, enhanced learning capacity, increased mental clarity, and a subtle mood-elevating effect. Noopept is frequently stacked with alpha-GPC or CDP-choline to support increased acetylcholine demand, and combined with other nootropics such as aniracetam or lion's mane for complementary mechanisms. Side effects are rare at standard doses but may include headache (often alleviated by choline supplementation), irritability, and insomnia if dosed late in the day. Note: Noopept is also sold under the name Omberacetam, which is its INN (International Nonproprietary Name).

Mechanism of Action

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111) is a dipeptide-derived nootropic that is rapidly metabolized to cyclo-prolylglycine, an endogenous neuropeptide, after crossing the blood-brain barrier. Its primary mechanism involves allosteric modulation of AMPA receptors, where it enhances glutamatergic transmission by increasing receptor sensitivity to glutamate and prolonging excitatory postsynaptic currents. Noopept also modulates NMDA receptor function by potentiating responses at the glycine co-agonist site, facilitating long-term potentiation (LTP) in hippocampal CA1 neurons, which is the cellular basis of memory formation.

Noopept significantly upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex through activation of the CREB transcription factor pathway. This neurotrophic effect promotes neuronal survival, dendritic branching, and synaptogenesis. Noopept also enhances alpha and beta1 oscillatory activity in the brain, correlating with improved attention and cognitive processing. It provides neuroprotection through multiple pathways: inhibiting glutamate-induced excitotoxicity by preventing excessive calcium influx, reducing oxidative stress by enhancing endogenous antioxidant defenses (SOD, catalase, glutathione), and blocking mitochondrial apoptotic cascades by preserving mitochondrial membrane potential and preventing cytochrome c release.

Therapeutically, noopept demonstrates cognitive enhancement at very low doses (10-30 mg daily, approximately 1000x lower than piracetam) due to its high bioavailability and potent receptor modulation. It has shown efficacy in preclinical models of Alzheimer's disease (reducing amyloid-beta aggregation and tau hyperphosphorylation), cerebrovascular insufficiency, and traumatic brain injury. Clinical studies in Russia report improvements in memory, attention, and emotional processing in patients with mild cognitive disorders. Its dual action of acute synaptic enhancement combined with chronic neurotrophic factor upregulation provides both immediate cognitive benefits and long-term neuroprotective effects.

Reconstitution Calculator

Research

Safety Profile

Common side effects include headaches, restlessness, dizziness, and irritability, especially at higher doses. It is contraindicated in individuals with severe hypertension, renal or hepatic impairment, and during pregnancy or lactation. Noopept may potentiate the effects of psychostimulants and anticoagulants, warranting caution with concurrent use.

Pharmacokinetic Profile